

## PROSTATIC HORMONAL IMPLANTS TREATMENT OF THE PROSTATE CANCER

### Abstract:

5 An improved method and products for the primary hormonal treatment of early stage, low  
and intermediate risk prostate cancers by prostatic implants of androgen suppressive  
drugs formulated as fused with a lipoid carrier or encapsulated in microcapsules or in  
Silastic capsules is provided. Such prostatic implants renders a constant slow-release of  
their contents to the prostate for extended periods by biodegradation and diffusion. It  
10 facilitates higher prostatic and lower systemic concentrations of androgen suppressive  
hormones. Because of their high prostatic and lower systemic concentrations, tumor  
control is much improved and the their systemic toxicity is minimized. Tumor control  
after such primary hormonal implant treatment is followed by clinical examinations and  
the biochemical tumor control is followed by periodic estimations of serum levels of PSA  
15 and acid phosphatase. More complex and expensive surgery or radiation therapy for this  
group of good prognostic early stage prostate cancer is reserved for those patients failing  
to this primary hormonal treatment. It will preserve potency more than by surgery or  
radiation therapy. Furthermore, it would reduce the cost of treatment for early stage  
prostate cancer significantly. Androgen suppressive hormonal implants to the prostate  
20 before, during or after lower dose conventional radiation therapy would also facilitate  
equal or better cure rates of localized prostate cancer as compared to the more complex  
and toxic higher dose radiation therapy.